BCL10 (MALT-Lymphoma Marker)(B Cell CLL/lymphoma 10,B Cell leukemia/lymphoma 10,CARD-containing molecule enhancing NF-kappa-B,CARD-like apoptotic protein,caspase-recruiting domain-containing protein,CED-3/ICH-1 prodomain

Antibodies / Antibodies-Apoptosis

-20°C

Supplied as a liquid in 10mM PBS. No preservative added. BSA-Free. Labeled with Fluorescein isothiocyanate (FITC).

Recombinant protein corresponding to aa122-168 from human BCL10.

BCL10, with an N-terminal caspase recruitment domain (CARD), is found in a number of apoptotic regulatory molecules. It was identified through its direct involvement in t(1; 14) of mucosa-associated lymphoid tissue (MALT) lymphoma. Expression of BCL10 was shown to induce NFkappaB activation in a NIK-dependent pathway. This MAb labels subpopulations of normal B and T cells and is a useful tool for the sub-classification of lymphomas. In MALT lymphomas with the t(1; 14) translocation, while 55% of MALT lymphomas lacking this translocation exhibited the same labeling pattern, although at a much lower level.

Applications:
Suitable for use in FLISA, Western Blot, Immunoprecipitation, Immunofluorescence, Flow Cytometry (Not Tested) and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
Immunohistochemistry (Frozen & Formalin fixed paraffin embedded): 0.5-1ug/ml/30min @ RT
Flow Cytometry (Not Tested): 0.5-1ug/10e6 cells
Immunofluorescence: 1-2ug/ml
Western Blot: 0.5-1ug/ml
Immunoprecipitation: 1-2g/500ug protein lysate
Optimal dilutions to be determined by the researcher.

Positive Control:
WEHI-231 or Ramos cells or lymphoma

Storage and Stability:
Store product at 4°C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20°C. Aliquots are stable at -20°C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer.
Caution: FITC conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Note: Applications are based on unconjugated antibody.